Relation of nonvalvular atrial fibrillation to body mass index (from the SPORTIF Trials)

American Journal of Cardiology

Volumn 118, Issue 1, 2016, Pages 72-78

  Proietti, Marco ^a,b   Lane, Deirdre A ^a   Lip, Gregory Y H ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE; XIMELAGATRAN;

ADVERSE OUTCOME; AGED; ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BODY MASS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAUSE OF DEATH; CONFERENCE PAPER; CONTROL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NONVALVULAR ATRIAL FIBRILLATION; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; BODY MASS INDEX; COHORT STUDIES; FEMALE; HUMANS; MALE; OBESITY; PREVALENCE; STROKE;

EID: 84966700123     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2016.04.013     Document Type: Conference Paper

References (30)

1. D. Mozaffarian, E.J. Benjamin, A.S. Go, D.K. Arnett, M.J. Blaha, M. Cushman, S. Ferranti de, J.-P. Després, H.J. Fullerton, V.J. Howard, M.D. Huffman, S.E. Judd, B.M. Kissela, D.T. Lackland, J.H. Lichtman, L.D. Lisabeth, S. Liu, R.H. Mackey, D.B. Matchar, D.K. McGuire, E.R. Mohler, C.S. Moy, P. Muntner, M.E. Mussolino, K. Nasir, R.W. Neumar, G. Nichol, L. Palaniappan, D.K. Pandey, M.J. Reeves, C.J. Rodriguez, P.D. Sorlie, J. Stein, A. Towfighi, T.N. Turan, S.S. Virani, J.Z. Willey, D. Woo, R.W. Yeh, M.B. Turner, J.-P. Despres, H.J. Fullerton, V.J. Howard, M.D. Huffman, S.E. Judd, B.M. Kissela, D.T. Lackland, J.H. Lichtman, L.D. Lisabeth, S. Liu, R.H. Mackey, D.B. Matchar, D.K. McGuire, E.R. Mohler 3rd, C.S. Moy, P. Muntner, M.E. Mussolino, K. Nasir, R.W. Neumar, G. Nichol, L. Palaniappan, D.K. Pandey, M.J. Reeves, C.J. Rodriguez, P.D. Sorlie, J. Stein, A. Towfighi, T.N. Turan, S.S. Virani, J.Z. Willey, D. Woo, R.W. Yeh, M.B. Turner, and American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart Disease and Stroke Statistics - 2015 Update: a report from the American Heart Association Circulation 131 2014 e29 e322
2. C.J. Lavie, P.A. McAuley, T.S. Church, R.V. Milani, and S.N. Blair Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox J Am Coll Cardiol 63 2014 1345 1354
3. G. Whitlock, S. Lewington, P. Sherliker, R. Clarke, J. Emberson, J. Halsey, N. Qizilbash, R. Collins, and R. Peto Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies Lancet 373 2009 1083 1096
4. P. Strazzullo, L. D'Elia, G. Cairella, F. Garbagnati, F.P. Cappuccio, and L. Scalfi Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants Stroke 41 2010 e418 e426
5. M.D. Jensen, D.H. Ryan, C.M. Apovian, J.D. Ard, A.G. Comuzzie, K.A. Donato, F.B. Hu, V.S. Hubbard, J.M. Jakicic, R.F. Kushner, M. Catherine, B.E. Millen, C.A. Nonas, F.X. Pi-sunyer, J. Stevens, V.J. Stevens, T.A. Wadden, B.M. Wolfe, and S.Z. Yanovski 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society Circulation 129 2014 S102 S138
6. J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, M. Verschuren, C. Albus, P. Benlian, G. Boysen, R. Cifkova, C. Deaton, S. Ebrahim, M. Fisher, G. Germano, R. Hobbs, A. Hoes, S. Karadeniz, A. Mezzani, E. Prescott, L. Ryden, M. Scherer, M. Syvänne, W.J.M. Scholte op Reimer, C. Vrints, D. Wood, J.L. Zamorano, and F. Zannad European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 33 2012 1635 1701
7. T.J. Wang, H. Parise, D. Levy, R.B. D'Agostino, P.A. Wolf, R.S. Vasan, and E.J. Benjamin Obesity and the risk of new-onset atrial fibrillation JAMA 292 2004 2471 2477
8. C.J. Nalliah, P. Sanders, H. Kottkamp, and J.M. Kalman The role of obesity in atrial fibrillation Eur Heart J 2015 ehv486 [E-pub ahead of print]
9. R.R. Huxley, J.R. Misialek, S.K. Agarwal, L.R. Loehr, E.Z. Soliman, L.Y. Chen, and A. Alonso Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study Circ Arrhythm Electrophysiol 7 2014 620 625
10. R.K. Pathak, M.E. Middeldorp, M. Meredith, A.B. Mehta, R. Mahajan, C.X. Wong, D. Twomey, A.D. Elliott, J.M. Kalman, W.P. Abhayaratna, D.H. Lau, and P. Sanders Long-Term Effect of Goal Directed Weight Management in an Atrial Fibrillation Cohort: A Long-term Follow-Up StudY (LEGACY Study) J Am Coll Cardiol 65 2015 2159 2169
11. A.O. Badheka, A. Rathod, M.A. Kizilbash, N. Garg, T. Mohamad, L. Afonso, and S. Jacob Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox Am J Med 123 2010 646 651
12. T.F. Overvad, L.H. Rasmussen, F. Skjøth, K. Overvad, G.Y.H. Lip, and T.B. Larsen Body mass index and adverse events in patients with incident atrial fibrillation Am J Med 126 2013 640.e9 640.e17
13. J.W. Eikelboom, L. Wallentin, S.J. Connolly, M. Ezekowitz, J.S. Healey, J. Oldgren, S. Yang, M. Alings, S. Kaatz, S.H. Hohnloser, H.-C. Diener, M.G. Franzosi, K. Huber, P. Reilly, J. Varrone, and S. Yusuf Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial Circulation 123 2011 2363 2372
14. M. Hori, M. Matsumoto, N. Tanahashi, S. Momomura, S. Uchiyama, S. Goto, T. Izumi, Y. Koretsune, M. Kajikawa, M. Kato, H. Ueda, K. Iwamoto, and M. Tajiri Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study - Circ J 76 2012 2104 2111
15. C.-H. Chen, M.-C. Chen, H. Gibbs, S.U. Kwon, S. Lo, Y.K. On, A. Rosman, N.C. Suwanwela, R.S. Tan, L.S. Tirador, and A. Zirlik Antithrombotic treatment for stroke prevention in atrial fibrillation: the Asian agenda Int J Cardiol 191 2015 244 253
16. S. Ogawa, K. Aonuma, H.-F. Tse, D. Huang, J.-L. Huang, J. Kalman, S. Kamakura, M. Nair, D.-G. Shin, M. Stiles, W. Siong Teo, and T. Yamane The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation J Arrhythmia 29 2013 190 200
17. J.L. Halperin Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V) Am Heart J 146 2003 431 438
18. G.Y.H. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J.G.M. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
19. R. De Caterina, S. Husted, L. Wallentin, F. Andreotti, H. Arnesen, F. Bachmann, C. Baigent, K. Huber, J. Jespersen, S.D. Kristensen, G.Y.H. Lip, J. Morais, L.H. Rasmussen, A. Siegbahn, F.W.A. Verheugt, and J.I. Weitz Vitamin K antagonists in heart disease: current status and perspectives (Section III) Thromb Haemost 110 2013 1087 1107
20. K. Senoo, and G.Y.H. Lip Body mass index and adverse outcomes in elderly patients with atrial fibrillation Stroke 47 2016 523 526
21. C.J. Lavie, and R.V. Milani Obesity and cardiovascular disease: the hippocrates paradox? J Am Coll Cardiol 42 2003 677 679
22. Z.J. Wang, Y.J. Zhou, B.Z. Galper, F. Gao, R.W. Yeh, and L. Mauri Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis Heart 101 2015 1631 1638
23. A. Sharma, C.J. Lavie, J.S. Borer, A. Vallakati, S. Goel, F. Lopez-Jimenez, A. Arbab-Zadeh, D. Mukherjee, and J.M. Lazar Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure Am J Cardiol 115 2015 1428 1434
24. F.M. Szymanski, G.Y.H. Lip, K.J. Filipiak, A.E. Platek, A. Hrynkiewicz-Szymanska, and G. Opolski Stroke risk factors beyond the CHA2DS2-VASc score: can we improve our identification of "high stroke risk" patients with atrial fibrillation? Am J Cardiol 116 2015 1781 1788
25. A. Ardestani, H.J. Hoffman, and H.A. Cooper Obesity and outcomes among patients with established atrial fibrillation Am J Cardiol 106 2010 369 373
26. A. Pandey, B.J. Gersh, D.K. McGuire, P. Shrader, L. Thomas, P.R. Kowey, K.W. Mahaffey, E. Hylek, S. Sun, P. Burton, J. Piccini, E. Peterson, and G.C. Fonarow Association of body mass index with care and outcomes in patients with atrial fibrillation: results from the ORBIT-AF Registry JACC Clin Electrophysiol 2015 [E-pub] http://dx.doi.org/10.1016/j.jacep.2015.12.001
27. E. Marijon, J.-Y. Le Heuzey, S. Connolly, S. Yang, J. Pogue, M. Brueckmann, J. Eikelboom, E. Themeles, M. Ezekowitz, L. Wallentin, and S. Yusuf Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study Circulation 128 2013 2192 2201
28. J.P. Piccini, S.R. Stevens, Y. Chang, D.E. Singer, Y. Lokhnygina, A.S. Go, M.R. Patel, K.W. Mahaffey, J.L. Halperin, G. Breithardt, G.J. Hankey, W. Hacke, R.C. Becker, C.C. Nessel, K.A.A. Fox, and R.M. Califf Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K ant Circulation 127 2013 224 232
29. R.K. Sandhu, J. Ezekowitz, U. Andersson, J. Alexander, C. Granger, S. Halvorsen, M. Hanna, Z. Hijazi, P. Jansky, R. Lopes, and L. Wallentin Body mass index and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Aristotle (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial J Am Coll Cardiol 65 2015 A284
30. C.J. Lavie, A. De Schutter, D.A. Patel, A. Romero-Corral, S.M. Artham, and R.V. Milani Body composition and survival in stable coronary heart disease: impact of lean mass index and body fat in the "obesity paradox" J Am Coll Cardiol 60 2012 1374 1380